retatrutide triple agonist gip glp-1 glucagon phase 3 2025 40mg The data just dropped —
Description
The emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor (GLP-1R) co-agonists offers a novel multi-receptor mechanism that can overcome these single-pathway limitations
Incretin based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes
Supports healthy blood sugar metabolism*
Stopping GLP-1 therapy triggers predictable metabolic shifts within weeks
A decrease in LAV was observed in the HFrEF population (WMD: -5.4 ml [95% CI: -8.8, -2.0]
